NASDAQ · LIVN
Healthcare · Medical - Devices
$74.93
Down-$1.50 (-1.96%)
Updated Oct 7, 2026, 1:20 PM
SID Score
5.4/10
Composite research score
Smart Money
58/100
Neutral
Price performance · LIVN
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
LIVN closed at $74.93 after 21 trading sessions, down 7.15% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $76.80 | $76.80 | $74.58 | $74.93 | 424.53K |
| Oct 5, 2026 | $75.555 | $76.90 | $74.23 | $76.43 | 558.95K |
| Oct 2, 2026 | $75.68 | $76.765 | $74.635 | $75.07 | 528.52K |
| Oct 1, 2026 | $76.44 | $77.15 | $74.47 | $74.70 | 767.26K |
| Sep 30, 2026 | $77.11 | $77.11 | $75.395 | $76.50 | 970.7K |
| Sep 29, 2026 | $76.71 | $77.15 | $76.13 | $76.99 | 567.97K |
| Sep 28, 2026 | $76.13 | $77.66 | $75.465 | $77.21 | 570.68K |
| Sep 25, 2026 | $75.44 | $77.46 | $75.12 | $76.63 | 745.31K |
| Sep 24, 2026 | $77.26 | $77.45 | $74.11 | $75.44 | 1.06M |
| Sep 23, 2026 | $78.39 | $79.02 | $76.70 | $77.16 | 493.06K |
| Sep 22, 2026 | $79.19 | $80.19 | $78.18 | $78.49 | 640.46K |
| Sep 21, 2026 | $78.39 | $78.63 | $76.83 | $78.17 | 579.15K |
| Sep 18, 2026 | $77.34 | $78.44 | $76.78 | $78.01 | 1.38M |
| Sep 17, 2026 | $79.23 | $79.23 | $77.51 | $77.79 | 627.28K |
| Sep 16, 2026 | $79.56 | $80.63 | $77.69 | $78.51 | 693.56K |
| Sep 15, 2026 | $80.19 | $80.2379 | $79.13 | $79.47 | 587.23K |
| Sep 14, 2026 | $78.70 | $80.77 | $78.30 | $80.63 | 553.53K |
| Sep 11, 2026 | $79.22 | $79.27 | $77.15 | $78.18 | 552.42K |
| Sep 10, 2026 | $78.11 | $78.88 | $77.37 | $78.18 | 426.01K |
| Sep 9, 2026 | $80.22 | $80.37 | $78.105 | $78.93 | 674.36K |
| Sep 8, 2026 | $81.44 | $81.83 | $80.155 | $80.70 | 472.96K |
The latest Smart Investors Daily articles mentioning LIVN.
Company
Market Activity
Research & News
LIVN research
Company profile and research snapshot.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 2, 2026 | Piper Sandler | Overweight | — |
| Aug 5, 2026 | Needham | Buy | — |
| Jul 15, 2026 | Mizuho | Outperform | — |
| Jul 1, 2026 | Freedom Capital Markets | Hold | — |
| Jun 22, 2026 | Keybanc | Overweight | — |
No generated briefing is available yet.
Yahoo · Sep 24, 2026
Tributary Capital Management released its second-quarter 2026 investor letter for “Multi Cap Core Equity Strategy”. You can download a copy of the letter here. The Tributary Multi Cap Core’s equity allocation underperformed in Q2, returning +12.5% against +15.3% for the S&P 1500 and +15.4% for the Russell 3000. Information Technology was the main driver of […]
Yahoo · Sep 23, 2026
GLOUCESTER, England, September 23, 2026--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2026 results on Wed., Nov. 4, 2026, at 1 p.m. Greenwich Mean Time (8 a.m. Eastern Standard Time). The Company will release its third-quarter 2026 results prior to the call.
Benzinga · Sep 15, 2026
Disclosed on September 14, Francesco Bianchi, Director at LivaNova (NASDAQ:LIVN), executed a substantial insider sell as per the latest SEC filing. What Happened: Bianchi's recent Form 4 filing with the U.S.
SeekingAlpha · Sep 14, 2026
LivaNova PLC (LIVN) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 11:30 AM EDTCompany ParticipantsVladimir Makatsaria - CEO...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LIVN.
